STORM Therapeutics Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STORM Therapeutics Ltd
Deal Snapshot: In addition to investigating the ADAR1 target with the UK biotech, Exelixis also has optioned a second candidate for non-Hodgkin’s lymphoma under its 2019 deal with Aurigene.
VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Drug Discovery Tools
- Drug Discovery Tools